FGF21 as a therapeutic reagent

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 214-228

  Zhao, Yang ^a   Dunbar, James D ^a   Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INSULIN; KLOTHO PROTEIN; ROSIGLITAZONE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FIBROBLAST GROWTH FACTOR;

ACUTE DRUG ADMINISTRATION; ADIPOCYTE DIFFERENTIATION; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHRONIC DRUG ADMINISTRATION; DIABETES MELLITUS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DYSLIPIDEMIA; FATTY LIVER; GENETIC MODEL; GLUCAGON RELEASE; GLUCOSE TRANSPORT; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG ADMINISTRATION; GENETICS; REVIEW;

ANIMALIA;

ANIMALS; CELL LINE; DRUG ADMINISTRATION SCHEDULE; FIBROBLAST GROWTH FACTORS; HUMANS; INDICATORS AND REAGENTS;

EID: 84859536164     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_14     Document Type: Article

References (120)

1. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974; 249(453):123-127
2. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2(3):REVIEWS3005
3. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16(2):139-149
4. Schlessinger J, Plotnikov AN, Ibrahimi OA et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell2000;6(3):743-750
5. Orr-Urtreger A, Bedford MT, Burakova T et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 1993; 158(2):475-486
6. Plotnikov AN, Hubbard SR, Schlessinger J et al. Crystal structures of two FGF-FGFR complexes reveal the determinants ofligand-receptor specificity. Cell 2000; 101(4):413-424
7. Plotnikov AN, Schlessinger J, Hubbard SRet al. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98(5):641-650
8. Kouhara H, Hadari YR, Spivak-Kroizman T et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997; 89(5):693-702
9. Hadari YR, Gotoh N, Kouhara H et al. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 2001; 98(15):8578-8583
10. Wong A, Lamothe B, Lee A et al. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA2002; 99(10):6684-6689
11. Lax I, Wong A, Lamothe B et al. The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell 2002; 10(4):709-719
12. Mohammadi M, Honegger AM, Rotin D et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 1991; 11(10):5068-5078
13. Deng CX, Wynshaw-Boris A, Shen MM et al. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 1994; 8(24):3045-3057
14. Yamaguchi TP, Harpal K, Henkemeyer M et al. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 1994; 8(24):3032-3044
15. Partanen J, Schwartz L, Rossant J. Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. Genes Dev 1998; 12(15):2332-2344
16. Xu X, Weinstein M, Li C et al. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10is essential for limb induction. Development 1998; 125(4):753-765
17. De Moerlooze L, Spencer-Dene B, Revest JM et al. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 2000; 127(3):483-492
18. Eswarakumar VP, Monsonego-Ornan E, Pines M et al. The IIIc alternative of Fgfr2 is a positive regulator ofbone formation. Development 2002; 129(16):3783-3793
19. Deng C, Wynshaw-Boris A, Zhou F et al. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84(6):911-921
20. Colvin JS, Bohne BA, Harding GW et al. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996; 12(4):390-397
21. Weinstein M, Xu X, Ohyama K et al. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis inthemurinelung. Development 1998; 125(18):3615-3623
22. Dode C, Hardelin JP. Kallmann syndrome: fibroblast growth factor signaling insufficiency? J Mol Med 2004; 82(11):725-734
23. Macdonald D, Aguiar RC, Mason PJ et al. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: areview. Leukemia 1995; 9(10):1628-1630
24. Roumiantsev S, Krause DS, Neumann CA et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 andBCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004; 5(3):287-298
25. Demiroglu A, Steer EJ, Heath C et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98(13):3778-3783
26. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008;237(1):18-27
27. Mohammadi M, Olsen SK, Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu ofheparan sulfate motifs. Curr Opin Struct Biol2005; 15(5):506-516
28. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 1987; 131(1):123-130
29. Flaumenhaft R, Moscatelli D, Rifkin DB. Heparin and heparan sulfate increase the radius of diffusion and action ofbasic fibroblast growth factor. JCellBiol 1990; 111(4):1651-1659
30. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115(6):1627-1635
31. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98(11):6500-6505
32. LundasenT, GalmanC, Angelin B etal. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260(6):530-536
33. Ogawa Y, Kurosu H, Yamamoto M et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007; 104(18):7432-7437
34. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120):770-774
35. Bhushan A, Itoh N, Kato S et al. Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis. Development 2001; 128(24):5109-5117
36. Ohuchi H, Hori Y, Yamasaki M et al. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun 2000; 277(3):643-649
37. Konishi M, Mikami T, Yamasaki M et al. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes. J Biol Chem 2000; 275(16):12119-12122
38. Sun HD, Malabunga M, Tonra JR et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007; 292(3):E964-E976
39. Hart AW, Baeza N, Apelqvist A et al. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000; 408(6814):864-868
40. Revest JM, Suniara RK, Kerr K et al. Development of the thymus requires signaling through the fibroblast growth factorreceptor R2-IIIb. J Immunol 2001; 167(4):1954-1961
41. Celli G, LaRochelle WJ, Mackem S et al. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 1998; 17(6):1642-1655
42. Elghazi L, Cras-Meneur C, Czernichow P et al. Role for FGFR2IIIb-mediated signals in controlling pancreatic endocrine progenitor cell proliferation. Proc Natl Acad Sci USA 2002; 99(6):3884-3889
43. Yu C, Wang F, Kan M et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275(20):15482-15489
44. Huang X, Yang C, Luo Y et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 56(10):2501-2510
45. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009; 284(17):11110-11120
46. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27(9):3417-3428
47. Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43(3):629-640
48. Ito S, Kinoshita S, Shiraishi N et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes anovel Klotho family protein. Mech Dev 2000; 98(1-2):115-119
49. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17(12):2393-2403
50. Holt JA, Luo G, Billin AN et al. Definition of a novel growth factor-dependent signal cascade for the suppression ofbile acidbiosynthesis. Genes Dev 2003; 17(13):1581-1591
51. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2(4):217-225
52. Tomlinson E, Fu L, John L et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143(5):1741-1747
53. Ito S, Fujimori T, Furuya A et al. Impaired negative feedback suppression ofbile acid synthesis in mice lacking betaKlotho. J Clin Invest 2005; 115(8):2202-2208
54. Nishimura T, Nakatake Y, Konishi M et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492(1):203-206
55. Ibrahimi OA, Zhang F, Eliseenkova AV et al. Biochemical analysis ofpathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 2004; 13(19):2313-2324
56. Kharitonenkov A, Dunbar JD, Bina HA et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008; 215(1):1-7
57. Suzuki M, Uehara Y, Motomura-Matsuzaka K et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22(4):1006-1014
58. Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity ofFGF19 and FGF21.J Biol Chem2007; 282(37):26687-26695
59. Murer H, Hernando N, Forster I et al. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80(4):1373-1409
60. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112(5):683-692
61. Wikvall K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int J Mol Med 2001; 7(2):201-209
62. ShimadaT, Kakitani M, Yamazaki Y etal. Targeted ablation ofFgf23 demonstrates an essential physiological role ofFGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113(4):561-568
63. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23(7):421-432
64. YoshidaT, Fujimori T,NabeshimaY. Mediation ofunusually high concentrations of1,25-dihydroxyvitaminD inhomozygous klotho mutantmice by increased expression ofrenal 1alpha-hydroxylase gene. Endocrinology 2002; 143(2):683-689
65. Inagaki T, Dutchak P, Zhao G et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor21. Cell Metab 2007; 5(6):415-425
66. Arner P, Pettersson A, Mitchell PJ et al. FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Lett 2008; 582(12):1725-1730
67. Badman MK, Pissios P, Kennedy AR et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5(6):426-437
68. Moyers JS, Shiyanova TL, Mehrbod F et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007;210(1):1-6
69. Muise ES, Azzolina B, Kuo DW et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008; 74(2):403-412
70. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressedby SIRT1 in adipocytes. Mol CellBiol 2008; 28(1):188-200
71. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008; 22(1):37-44
72. Izumiya Y, Bina HA, Ouchi N et al.FGF21 is an Akt-regulate dmyokine. FEBS Lett 2008; 582(27):3805-3810
73. Izumiya Y, Hopkins T, Morris C et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008; 7(2):159-172
74. Lundasen T, Hunt MC, Nilsson LM et al. PPARalpha is a key regulator ofhepatic FGF21. Biochem Biophys Res Commun 2007; 360(2):437-440
75. Wente W, Efanov AM, Brenner M et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55(9):2470-2478
76. Leibowitz G, Uckaya G, Oprescu AI et al. Glucose-regulated proinsulin gene expression is required for adequate insulin production during chronic glucose exposure. Endocrinology 2002; 143(9):3214-3220
77. Bollheimer LC, Skelly RH, Chester MW et al. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase inproinsulinbiosynthesis translation. J Clin Invest 1998; 101(5):1094-1101
78. Inagaki T, Lin VY, Goetz R et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab2008; 8(1):77-83
79. Coskun T, Bina HA, Schneider MA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149(12):6018-6027
80. Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58(1):250-259
81. Berglund ED, Li CY, Bina HA et al. Fibroblast growth factor 21 controls glycemia via regulation ofhepatic glucose flux and insulin sensitivity. Endocrinology 2009; 150(9):4084-4093
82. Huang X, Yu C, Jin C et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006; 45(12):934-942
83. Xu J, Stanislaus S, Chinookoswong N et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models-Association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009
84. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009; 284(15):10023-10033
85. Wu X, Lemon B, Li X et al. C-terminal tail of FGF19 determines its specificity toward Klotho coreceptors. J Biol Chem 2008; 283(48):33304-33309
86. Micanovic R, Raches DW, Dunbar JD et al. Different roles of N- and C- termini in the functional activity ofFGF21. J Cell Physiol 2009; 219(2):227-234
87. Yie J, Hecht R, Patel J et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 2009; 583(1):19-24
88. Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 2008; 23(9):1509-1518
89. Choi M, Moschetta A, Bookout AL et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12(11):1253-1255
90. Nicholes K, Guillet S, Tomlinson E et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160(6):2295-2307
91. Hashimoto T, Cook WS, Qi C et al. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275(37):28918-28928
92. Kersten S, Seydoux J, Peters JM etal. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103(11):1489-1498
93. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96(13):7473-7478
94. Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007; 28(12):2382-2386
95. Uebanso T, Taketani Y, FukayaM et al. Hypocaloric high-protein diet improves fatty liver andhypertriglyceridemia in sucrose-fed obese rats via two pathways. Am J Physiol Endocrinol Metab 2009; 297(1):E76-E84
96. Palou M, Priego T, Sanchez J et al. Sequential changes inthe expression of genes involved in lipid metabolism in adipose tissue and liver in response to fasting. Pflugers Arch 2008; 456(5):825-836
97. Badman MK, Koester A, Flier JS et al. Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptationto Ketosis. Endocrinology 2009; 150(11):Epub as doi:10.1210/en.2009-0523
98. Schafer SA, Hansen BC, Volkl A et al. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in nonhuman primates. Biochem Pharmacol 2004; 68(2):239-251
99. Angeloni SV, Glynn N, Ambrosini G et al. Characterization of the rhesus monkey ghrelin gene and factors influencing ghrelin gene expression and fasting plasma levels. Endocrinology 2004; 145(5):2197-2205
100. Oliver WR Jr, Shenk JL, Snaith MR et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98(9):5306-5311
101. Walston J, Lowe A, Silver K et al. The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Gene 1997; 188(2):207-213
102. Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148(2):774-781
103. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15(3):243-250
104. Cohen P, Miyazaki M, Socci ND et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002; 297(5579):240-243
105. Handschin C, Spiegelman BM. Peroxisomeproliferator-activatedreceptor gamma coactivator 1 coactivators, energy homeostasis and metabolism. Endocr Rev 2006; 27(7):728-735
106. Galman C, Lundasen T, Kharitonenkov A et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8(2):169-74
107. Bjursell M, Gerdin AK, Lelliott CJ et al. Acutely reduced locomotor activity is a major contributor to Western diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2008; 294(2):E251-E260
108. Winegar DA, Brown PJ, Wilkison WO et al. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001; 42(10):1543-1551
109. Guerre-Millo M, Gervois P, Raspe E et al. Peroxisome proliferator- activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275(22):16638-16642
110. Butler AE, Janson J, Bonner-Weir S et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1):102-110
111. Zhang X, Yeung DC, Karpisek M et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57(5):1246-1253
112. Hojman P, Pedersen M, Nielsen AR et al. Fibroblast growth factor-21 is induced inhuman skeletal muscles by hyperinsulinemia. Diabetes 2009; 58(12):2797-801
113. Li L, Yang G, Ning H et al. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008; 82(2):209-213
114. Chen WW, Li L, Yang GY et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116(1):65-68
115. Durovcova V, Marek J, Hana V et al. Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushings syndrome. Physiol Res 2010; 59(3):415-22
116. Stein S, Bachmann A, Lossner U et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 2009; 32(1):126-128
117. Dostalova I, Kavalkova P, Haluzikova D et al. Plasma concentrations of fibroblast growth factors 19 and 21in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93(9):3627-3632
118. Bartak V, Vybiral S, Papezova H et al. Basal and exercise-induced sympathetic nervous activity and lipolysis in adipose tissue of patients with anorexia nervosa. Eur J Clin Invest 2004; 34(5):371-377
119. Xu A, Tso AW, Cheung BM et al. Circulating adipocyte-fatty acid binding protein levels predict the development ofthemetabolic syndrome: a 5-yearprospective study. Circulation2007; 115(12):1537-1543
120. Mraz M, Bartlova M, Lacinova Z et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71(3):369-375